# Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Source: https://onco.cc/trials/nct06947291/  
OnCo record `nct06947291` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Glumetinib and Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.

## Summary

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06947291 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 350 participants planned, started 2025-06-04 and due to reach its primary completion in 2027-04-30. Interventions recorded: Glumetinib Tablets and Docetaxel for Injection (Albumin-bound).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06947291
- Phase: 2
- Setting: A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors With MET Overexpression and/or Amplification
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT06947291: https://clinicaltrials.gov/study/NCT06947291

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Glumetinib](https://onco.cc/drugs/glumetinib/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06947291.json